Concepts (84)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gigantism | 1 | 2019 | 1 | 0.640 |
Why?
|
| Prognathism | 1 | 2019 | 2 | 0.640 |
Why?
|
| Thyrotropin | 1 | 2017 | 48 | 0.550 |
Why?
|
| Adolescent Health Services | 1 | 2016 | 5 | 0.530 |
Why?
|
| Transition to Adult Care | 1 | 2016 | 3 | 0.530 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 22 | 0.530 |
Why?
|
| Thyroxine | 1 | 2017 | 80 | 0.530 |
Why?
|
| Hypothyroidism | 1 | 2017 | 69 | 0.520 |
Why?
|
| Quality of Health Care | 1 | 2016 | 102 | 0.490 |
Why?
|
| Body Mass Index | 1 | 2017 | 458 | 0.460 |
Why?
|
| Hydrocortisone | 3 | 2015 | 39 | 0.360 |
Why?
|
| Adolescent | 6 | 2019 | 2172 | 0.330 |
Why?
|
| Adrenal Hyperplasia, Congenital | 2 | 2004 | 3 | 0.290 |
Why?
|
| Androstenedione | 2 | 2004 | 6 | 0.240 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2004 | 1 | 0.230 |
Why?
|
| Neonatal Screening | 1 | 2004 | 6 | 0.230 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 35 | 0.230 |
Why?
|
| Child | 5 | 2021 | 1295 | 0.190 |
Why?
|
| Insulin | 1 | 2021 | 89 | 0.180 |
Why?
|
| Inpatients | 1 | 2021 | 125 | 0.170 |
Why?
|
| Child, Preschool | 2 | 2017 | 641 | 0.150 |
Why?
|
| Growth Charts | 1 | 2017 | 2 | 0.140 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 6 | 0.140 |
Why?
|
| Thyroid Function Tests | 1 | 2017 | 12 | 0.140 |
Why?
|
| Humans | 9 | 2021 | 27074 | 0.140 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 35 | 0.140 |
Why?
|
| Policy Making | 1 | 2016 | 12 | 0.130 |
Why?
|
| Pediatric Obesity | 1 | 2017 | 44 | 0.130 |
Why?
|
| Adolescent Behavior | 1 | 2016 | 26 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2016 | 120 | 0.130 |
Why?
|
| Self Care | 1 | 2016 | 89 | 0.120 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1144 | 0.120 |
Why?
|
| Adrenal Insufficiency | 1 | 2015 | 6 | 0.120 |
Why?
|
| Social Support | 1 | 2016 | 196 | 0.120 |
Why?
|
| Saliva | 1 | 2015 | 52 | 0.120 |
Why?
|
| Male | 5 | 2019 | 14772 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 261 | 0.120 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 10 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 891 | 0.110 |
Why?
|
| Chicago | 1 | 2017 | 949 | 0.110 |
Why?
|
| Critical Illness | 1 | 2015 | 117 | 0.110 |
Why?
|
| Vitamin D | 1 | 2014 | 39 | 0.110 |
Why?
|
| United States | 2 | 2016 | 2035 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2017 | 3538 | 0.100 |
Why?
|
| Chromatography, Liquid | 3 | 2015 | 23 | 0.100 |
Why?
|
| Young Adult | 1 | 2017 | 1994 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2015 | 642 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 474 | 0.080 |
Why?
|
| Female | 4 | 2017 | 15213 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 482 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2004 | 102 | 0.060 |
Why?
|
| Progesterone | 1 | 2003 | 20 | 0.050 |
Why?
|
| Steroids | 1 | 2003 | 23 | 0.050 |
Why?
|
| Hypocalcemia | 1 | 2003 | 3 | 0.050 |
Why?
|
| Mosaicism | 1 | 2003 | 9 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 37 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 1890 | 0.050 |
Why?
|
| Mass Screening | 1 | 2003 | 167 | 0.050 |
Why?
|
| Mutation | 1 | 2003 | 348 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2021 | 73 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 20 | 0.030 |
Why?
|
| Population | 1 | 2014 | 5 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 85 | 0.030 |
Why?
|
| Poverty | 1 | 2014 | 96 | 0.030 |
Why?
|
| Infant | 1 | 2015 | 564 | 0.030 |
Why?
|
| Parents | 1 | 2014 | 113 | 0.030 |
Why?
|
| Educational Status | 1 | 2014 | 293 | 0.030 |
Why?
|
| Prevalence | 1 | 2014 | 443 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2015 | 1778 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2003 | 1 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2003 | 34 | 0.010 |
Why?
|
| Protein Denaturation | 1 | 2003 | 1 | 0.010 |
Why?
|
| Immunoassay | 1 | 2003 | 38 | 0.010 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2003 | 2 | 0.010 |
Why?
|
| DNA Fingerprinting | 1 | 2003 | 6 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2003 | 13 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 29 | 0.010 |
Why?
|
| Exons | 1 | 2003 | 33 | 0.010 |
Why?
|
| Pedigree | 1 | 2003 | 65 | 0.010 |
Why?
|
| Haplotypes | 1 | 2003 | 58 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 137 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 310 | 0.010 |
Why?
|
| Calcium | 1 | 2003 | 371 | 0.010 |
Why?
|
| Adult | 1 | 2003 | 7831 | 0.010 |
Why?
|